Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 7/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699869 | 0.88 | EGFR (0.51) | EGFR | |
| SCHEMBL19337151 | 0.86 | HTR6 (0.44) | CCNB2CDK1CCNB1CCNB3HTR6 | |
| SCHEMBL19337160 | 0.85 | CCNB2 (0.41) | CCNB2CDK1CCNB1CCNB3HTR6 | |
| SCHEMBL3819496 | 0.85 | HTR6 (0.58) | HTR6DRD2HTR2AHTR7FLT3 | |
| SCHEMBL29419125 | 0.80 | MKNK1 (0.50) | DYRK1AEGFRFLT3CDK2 | |
| SCHEMBL5096322 | 0.80 | MKNK1 (0.50) | DYRK1AEGFRFLT3CDK2 | |
| SCHEMBL17683240 | 0.77 | HTT (0.55) | CCNB2CDK1CCNB1CCNB3DYRK1A | |
| SCHEMBL30459782 | 0.77 | HTT (0.55) | CCNB2CDK1CCNB1CCNB3DYRK1A | |
| SCHEMBL17542623 | 0.76 | MKNK1 (0.53) | DYRK1ADYRK1BCDK2 | |
| SCHEMBL17542604 | 0.76 | MKNK2 (0.53) | DYRK1ACYP3A4CYP2D6DYRK1BCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | InventisBio Co., Ltd. (CN) | 2021-12-21 | — | — | US | disclosed |
| EP-3885344-A2 | PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | INVENTISBIO SHANGHAI LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2019-01-15 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | CCNB2 2525/4885CDK1 374/4885CCNB1 1740/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | CCNB2 2525/4885CDK1 374/4885CCNB1 1740/4885 |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, TP53 | CCNB2 3108/4885CDK1 1256/4885CCNB1 2488/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | CCNB2 2802/4885CDK1 598/4885CCNB1 2168/4885 |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, DPYD | CCNB2 2525/4885CDK1 374/4885CCNB1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.